股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江太美醫療科技股份有限公司 (「本公司」) 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02576 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,592,533 | RMB | | 1 | RMB | | 200,592,533 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 200,592,533 | RMB | | 1 | RMB | | 200,592,533 | ...

Summary of Key Points Core Viewpoint - On November 4, 38 Hong Kong-listed companies conducted share buybacks, totaling 62.68 million shares and an aggregate amount of HKD 294 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 18 million shares for HKD 76.11 million, with a highest price of HKD 4.260 and a lowest price of HKD 4.210, bringing its total buyback amount for the year to HKD 233 million [1][2]. - COSCO Shipping Holdings repurchased 4.5 million shares for HKD 61.70 million, with a highest price of HKD 13.960 and a lowest price of HKD 13.600, accumulating a total buyback amount of HKD 45.30 billion for the year [1][2]. - Pacific Shipping repurchased 10 million shares for HKD 26.09 million, with a highest price of HKD 2.640 and a lowest price of HKD 2.580, totaling HKD 22.91 million in buybacks for the year [1][2]. Group 2: Notable Companies - The largest buyback amount on November 4 was by China Feihe at HKD 76.11 million, followed by COSCO Shipping Holdings at HKD 61.70 million [1][2]. - In terms of share quantity, China Feihe led with 18 million shares repurchased, followed by Pacific Shipping with 10 million shares and Sinopec with 5.15 million shares [1][2]. - Noteworthy is that companies like Fenbi and Taimei Medical Technology conducted their first buybacks of the year on this date [2].

Core Viewpoint - Taimei Medical Technology (02576) announced a share buyback of 167,400 shares at a cost of HKD 704,000 on November 4, 2025 [1] Group 1 - The company is actively engaging in share repurchase to potentially enhance shareholder value [1] - The total number of shares repurchased is 167,400 [1] - The total expenditure for the buyback is HKD 704,000 [1]

Core Viewpoint - Taimei Medical Technology (02576) announced a share buyback plan, investing HKD 704,000 to repurchase 167,400 shares [1] Group 1 - The company will execute the buyback on November 4, 2025 [1]

Core Viewpoint - Taimei Medical Technology (02576.HK) announced a share buyback of 167,000 shares at a cost of HKD 704,000 on November 4 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 704,000 [1] - The number of shares repurchased was 167,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 浙江太美醫療科技股份有限公司 (「本公司」) 呈交日期： 2025年11月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02576 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現 ...

致：香港交易及結算所有限公司 公司名稱: 浙江太美醫療科技股份有限公司 (「本公司」) 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 備註： 第 1 頁 共 11 頁 v 1.1.1 FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02576 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 200,592,533 | RMB | | 1 RMB | | 200,592,533 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 200,592,533 | RMB | | 1 RMB | | ...

Core Insights - Zhejiang Province's Economic and Information Technology Department has released the "2025 Zhejiang Province Artificial Intelligence Application Scenarios List," which includes "AI Empowered Innovative Applications for New Drug Clinical Research" submitted by Taimei Medical Technology [1] - This selection is part of Zhejiang's efforts to implement the State Council's strategy on artificial intelligence-driven industrialization, aiming to accelerate AI innovation applications and foster deep industrial transformation [1] - The selected scenarios are required to be typical, innovative, demonstrative, and replicable [1] Company Overview - Taimei Medical Technology is a pioneer in the research and application of intelligent technology in the vertical field, having developed the "Wensi Intelligent Platform" that integrates advanced AI models and dynamic learning algorithms [1] - The platform provides reliable, usable, and perceptible AI agents for pharmaceutical research and digital marketing, including products like iDM, iCTA, iMAP, iPV, and the Wujie AI series, along with end-to-end intelligent solutions to enhance overall efficiency and commercial performance in drug development [1] Future Outlook - The company aims to continue its vision of "releasing intelligent power to make health accessible," focusing on technological research and building next-generation intelligent infrastructure for the pharmaceutical industry [2] - By driving industry transformation with smart technology and innovative thinking, the company seeks to make drug innovation more efficient, ensure safer patient medication, and improve access to quality medicines while reducing the financial burden on patients [2]

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江太美醫療科技股份有限公司 (「本公司」) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02576 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,592,533 | RMB | | 1 | RMB | | 200,592,533 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 200,592,533 | RMB | | | 1 RMB | | 200,592,533 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | ...

Core Viewpoint - The company, Taimei Medical Technology (02576.HK), has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a significant step towards enhancing its market presence and liquidity [1] Summary by Sections - **H-share Conversion** - The company has applied to convert a total of 363,186,467 shares of domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - **Regulatory Approval** - The conversion of domestic shares into H-shares will occur once all necessary approvals and filings from regulatory bodies, including the CSRC and the Stock Exchange, are obtained and all applicable laws and regulations are met [1] - **Shareholder Meeting Requirement** - According to the company's articles of association, there is no need to convene a shareholders' meeting to approve the conversion and listing of the shares [1]